Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Can-Fite BioPharma stock

Learn how to easily invest in Can-Fite BioPharma stock.

Can-Fite BioPharma Ltd is a biotechnology business based in the US. Can-Fite BioPharma shares (CANF) are listed on the NYSE MKT and all prices are listed in US Dollars. Can-Fite BioPharma employs 8 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Can-Fite BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CANF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Can-Fite BioPharma stock price (NYSE MKT: CANF)

Use our graph to track the performance of CANF stocks over time.

Can-Fite BioPharma shares at a glance

Information last updated 2022-01-11.
Latest market close$1.31
52-week range$0.94 - $3.07
50-day moving average $1.30
200-day moving average $1.84
Wall St. target price$6.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.69

Buy Can-Fite BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
$125 - $625
Open and fund an account with $25,000 - $250,000+

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Can-Fite BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Can-Fite BioPharma price performance over time

Historical closes compared with the close of $1.31 from 2022-01-14

1 week (2022-01-07) 2.34%
1 month (2021-12-17) 3.15%
3 months (2021-10-15) -15.48%
6 months (2021-07-16) -43.29%
1 year (2021-01-15) -31.05%
2 years (2020-01-16) -52.36%
3 years (2019-01-16) 1.55%
5 years (2017-01-13) 2.36

Can-Fite BioPharma financials

Revenue TTM $799,000
Gross profit TTM $763,000
Return on assets TTM -55.28%
Return on equity TTM -128.53%
Profit margin 0%
Book value $0.48
Market capitalisation $27.4 million

TTM: trailing 12 months

Can-Fite BioPharma share dividends

We're not expecting Can-Fite BioPharma to pay a dividend over the next 12 months.

Have Can-Fite BioPharma's shares ever split?

Can-Fite BioPharma's shares were split on a 1:15 basis on 9 May 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Can-Fite BioPharma shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Can-Fite BioPharma shares which in turn could have impacted Can-Fite BioPharma's share price.

Can-Fite BioPharma share price volatility

Over the last 12 months, Can-Fite BioPharma's shares have ranged in value from as little as $0.9402 up to $3.07. A popular way to gauge a stock's volatility is its "beta".

CANF.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Can-Fite BioPharma's is 1.6889. This would suggest that Can-Fite BioPharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Can-Fite BioPharma overview

Can-Fite BioPharma Ltd. , a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.

Frequently asked questions

What percentage of Can-Fite BioPharma is owned by institutions?
Currently 8.212% of Can-Fite BioPharma shares are held by institutions.
How many people work for Can-Fite BioPharma?
Latest data suggests 8 work at Can-Fite BioPharma.
When does the fiscal year end for Can-Fite BioPharma?
Can-Fite BioPharma's fiscal year ends in December.
Where is Can-Fite BioPharma based?
Can-Fite BioPharma's address is: 10 Bareket Street, Petah Tikva, Israel, 4951778
What is Can-Fite BioPharma's ISIN number?
Can-Fite BioPharma's international securities identification number is: US13471N2018
What is Can-Fite BioPharma's CUSIP number?
Can-Fite BioPharma's Committee on Uniform Securities Identification Procedures number is: 13471N102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site